Clinical Trial Update: Vonafexor in Patients With Impaired Renal Function and Suspected MASH (Metabolic Dysfunction-associated Steatohepatitis) [Phase 2]

View source ↗

Summary

The Phase 2 trial of vonafexor in patients with impaired renal function and suspected metabolic dysfunction-associated steatohepatitis has been terminated.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Kidney Disease
• Metabolic Dysfunction-associated Steatohepatitis

Drugs mentioned

• Vonafexor (vonafexor)

Snippet

Sponsor: Enyo Pharma | Conditions: Chronic Kidney Disease Stage 2, Chronic Kidney Disease Stage 3 | Phase 2 | Status: TERMINATED